Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 4/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 2/20 | 0.38 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.38 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31653046 | 1.00 | AHCY (0.49) | AHCYPNPLMNATP53HTT | |
| SCHEMBL12238023 | 1.00 | AHCY (0.49) | AHCYPNPLMNATP53HTT | |
| SCHEMBL30662535 | 1.00 | AHCY (0.49) | AHCYPNPLMNATP53HTT | |
| SCHEMBL2524218 | 1.00 | AHCY (0.49) | AHCYPNPLMNATP53HTT | |
| SCHEMBL12214156 | 1.00 | AHCY (0.49) | AHCYPNPLMNATP53HTT | |
| SCHEMBL24695938 | 0.91 | AHCY (0.39) | AHCYPNPLMNATP53HTT | |
| SCHEMBL26125992 | 0.91 | AHCY (0.39) | AHCYPNPLMNATP53HTT | |
| SCHEMBL9548688 | 0.91 | AHCY (0.50) | AHCYPNPLMNATP53HTT | |
| SCHEMBL9548676 | 0.91 | AHCY (0.50) | AHCYPNPLMNATP53HTT | |
| SCHEMBL12237558 | 0.91 | AHCY (0.50) | AHCYPNPLMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177202-B1 | 4'-C-ETHYNYL PURINE NUCLEOSIDES | YAMASA CORP (JP) | 2003-09-24 | — | — | EP | claimed |
| EP-1177202-A1 | 4'-C-ETHYNYL PURINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2002-02-06 | — | — | EP | claimed |
| US-6333315-B1 | FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-12-25 | — | — | US | claimed |
| WO-2000069877-A1 | 4'-C-ETHYNYL PURINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2000-11-23 | — | — | WO | claimed |
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | PRIMEFOUR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | PRIMEFOUR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2022256625-A1 | LINE-1 INHIBITORS AS COGNITIVE ENHANCERS | TRANSPOSON THERAPEUTICS, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| EP-1177202-B1 | 4'-C-ETHYNYL PURINE NUCLEOSIDES | YAMASA CORP (JP) | 2003-09-24 | — | — | EP | disclosed |
| US-6403568-B1 | FOR THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) | YAMASA CORPORATION (JP) | 2002-06-11 | — | — | US | disclosed |
| US-20020022722-A1 | 4'-C-ethynyl pyrimidine nucleoside compounds | OHRUI HIROSHI (JP) | 2002-02-21 | — | — | US | disclosed |
| US-6333315-B1 | FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6291670-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022722-A1 | 4'-C-ethynyl pyrimidine nucleoside compounds | PNP, TYMP, NUDT1 | AHCY 656/4885PNP 1/4885LMNA 3211/4885 |
| US-20230293526-A1 | METHOD FOR TREATING CANCER WITH A REVERSE TRANSCRIPTASE INHIBITOR | TYMP, TYMS, DCTD | AHCY 248/4885PNP 50/4885LMNA 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.